Back to Search
Start Over
Small-molecule drugs of colorectal cancer: Current status and future directions.
- Source :
-
BBA: Molecular Basis of Disease . Jan2024, Vol. 1870 Issue 1, pN.PAG-N.PAG. 1p. - Publication Year :
- 2024
-
Abstract
- Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the world's fourth most deadly cancer. CRC, as a genetic susceptible disease, faces significant challenges in optimizing prognosis through optimal drug treatment modalities. In recent decades, the development of innovative small-molecule drugs is expected to provide targeted interventions that accurately address the different molecular characteristics of CRC. Although the clinical application of single-target drugs is limited by the heterogeneity and high metastasis of CRC, novel small-molecule drug treatment strategies such as dual/multiple-target drugs, drug repurposing, and combination therapies can help overcome these challenges and provide new insights for improving CRC treatment. In this review, we focus on the current status of a range of small molecule drugs that are being considered for CRC therapy, including single-target drugs, dual/multiple-target drugs, drug repurposing and combination strategies, which will pave the way for targeting CRC vulnerabilities with small-molecule drugs in future personalized treatment. [Display omitted] • The current status of CRC small-molecule drugs. • CRC related progress in recent years. • Signaling pathway and protein target of CRC therapeutic. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09254439
- Volume :
- 1870
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- BBA: Molecular Basis of Disease
- Publication Type :
- Academic Journal
- Accession number :
- 173519545
- Full Text :
- https://doi.org/10.1016/j.bbadis.2023.166880